Galen continues to invest in both internal development projects and external licensing opportunities in order to build a portfolio of innovative proprietary products with global potential.
To date, Galen has established successful collaborations in a number of European markets with Laxido®, and has initiated partnerships with like-minded companies in other key markets, with the aim of building a network of strategic partners around the world, which will enable Galen to commercialise products globally in the future.
Galen is currently looking for partners for the following products:
- Laxido® (macrogol 3350, sodium chloride, sodium hydrogen carbonate, potassium chloride) oral sachets: Laxido® is approved in 13 EU markets and marketed by Tramedico in Benelux, Nordic Pharma in Sweden/Finland and Ecupharma in Italy. Galen is looking to identify potential partners to distribute Laxido® in other markets around the world.
If you would like to discuss partnering opportunities for Galen products within your market or region, please contact our business development team.